Skip to main content

Advertisement

Log in

Delayed emesis: incidence, pattern, prognostic factors and optimal treatment

  • Review Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Delayed emesis has been arbitrarily defined as vomiting and/or nausea beginning, or persisting for, more than 24 h after chemotherapy administration. Acute emesis is the most important prognostic factor for delayed emesis. Owing to the relatively high incidence and severity all patients treated with cisplatin ≥50 mg/m2 should receive antiemetic prophylaxis. In these patients a combination of dexamethasone plus metoclopramide or a 5-HT3 antagonist is the most efficacious regimen. All patients submitted to moderately emetogenic chemotherapy, such as cyclophosphamide, carboplatin, doxorubicin and epirubicin, should also receive antiemetic prophylaxis with oral dexamethasone to prevent delayed emesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Fausto Roila.

Additional information

Electronic Publication

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roila, F., Donati, D., Tamberi, S. et al. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 10, 88–95 (2002). https://doi.org/10.1007/s005200100295

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s005200100295

Navigation